BioSphere Medical Embosphere
This article was originally published in The Gray Sheet
Executive Summary
Bioengineered microspheres gain 510(k) clearance for the minimally invasive treatment of vascular malformations and tumors via embolization. Embosphere will be directly marketed by a team of reps supported by a clinical team. BioSphere launched Phase I trials of the device in uterine artery embolization for uterine fibroid treatment in January
You may also be interested in...
BioSphere Pitches Uterine Fibroid Embolization Alternative To Hysterectomy
BioSphere Medical maintains that 180,000 additional women per year who would normally receive hysterectomies will be candidates for its Embosphere Microspheres uterine fibroid embolization now that the procedure has received FDA go-ahead
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.